This is a past event
External event
HST evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England. Our HST programme evaluates technologies for very rare, and often significantly life-limiting, diseases that need the specific considerations and flexibilities permitted by the programme. Join Jonathan Benger, NICE’s deputy chief executive as he discusses our plans to refine and revise the routing criteria to determine which topics should progress through the programme. Hear how this will help ensure that our decision-making is more transparent, consistent, efficient and predictable. Discover how this will impact access to treatments for very rare diseases and how you can share your views about our plans.
To find out more and register visit the event webpage.
- Hosted by
- Online
- Contact
-
The event is free and open to all.